Apr 22 |
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
|
Apr 11 |
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
|
Apr 1 |
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
|
Mar 26 |
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
|
Mar 13 |
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts
|
Mar 10 |
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations
|
Mar 8 |
Ocuphire Pharma GAAP EPS of -$0.21 misses by $0.21, revenue of $1.69M misses by $4.27M
|
Mar 8 |
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
|
Feb 23 |
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
|
Feb 14 |
Ocuphire Pharma appointed Nirav Jhaveri as CFO
|